Thursday, 18 Jan 2018

You are here

Biologics Before Triple DMARD is Not Cost Effective in Rheumatoid Arthritis

Stepping up to biologic therapy when methotrexate (MTX) monotherapy fails was not shown to be cost effective, compared to first trying triple therapy, in a rheumatoid arthritis (RA) study published in Annals of Internal Medicine.

The RACAT (Rheumatoid Arthritis Comparison of Active Therapies) trial was a follow up to the TEAR study, both studying the comparative timing and use of triple therapy (MTX plus hydroxychloroquine plus sulfasalazine) versus etanercept (ETN) and MTX in RA patients failing MTX therapy alone,  Whereas TEAR studied these regimens in early RA patients, RACAT focused on patients with established RA.  Both RACAT and TEAR showed non-inferiority of triple therapy to the more aggressive and expensive biologic regimen (ETN + MTX).

The current study is a subanalysis for the the 353 participants in the RACAT trial and a lifetime analysis that extrapolated costs and outcomes by using a decision analytic cohort model.

MTX inadequate responders were randomized to either ETN-MTX or triple therapy and the incremental costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness rations (ICERs) at 24 months and a lifetime were compared.  

Results showed treating with the biologic therapy first provided marginally more benefits, but an amount that would not be detectable to patients. The lifetime analysis suggested that first-line biologic treatment would result in 0.15 additional lifetime QALYs, but this gain would cost an incremental $77,290, leading to an incremental cost-effectiveness ratio of $521,520 per QALY per patient, a figure far above what is considered acceptable to the U.S. health care system.

The authors conclude that patients, unless contraindicated, should switch to triple therapy first before switching to a biologic strategy. The authors cite literature showing this is a strategy that many patients would prefer anyway, since it could reduce their overall out-of-pocket costs.

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

IL-1 and IL-6 Inhibition Preferred in Systemic JIA

Since 2000, the German Biologics register (BiKeR) has prospectively enrolled children with juvenile idiopathic arthritis to assess outcomes with biologic therapies.  A new report evaluates the efficacy and safety of etanercept (ETA), tocilizumab (TOC) and the interleukin-1 inhibitors (anakinra and canakinumab) (IL-1i) in those with systemic onset juvenile idiopathic arthritis JIA (sJIA).

Increasing Adverse Events Seen with Higher Disease Activity in Early RA

Researchers in the NEO-RACo Study Group studied adverse events (AEs) in relation to disease activity in patients with early rheumatoid arthritis (RA).

Small Joint Surgeries Drop Among RA Patients

The rate of small - but not large - joint surgery has dropped among patients with rheumatoid arthritis since 1995, a retrospective review of orthopedic surgeries found. By 2015, less than 1% of patients per year underwent small joint surgery, reported Ashima Makol, MD, of the Mayo Clinic in Rochester, Minnesota, and colleagues in Arthritis Care & Research. 

Despite Increasing Metric Use, They Are Not Widespread in Rheumatoid Care

The Journal of Rheumatology has published a nationwide survey of US rheumatologists and shown that despite trends for increasing metric assessments, nearly half of rheumatoid arthritis (RA) patients are not routinely assessed with a disease activity metric and the evidence they use these in a treat-to-target (T2T) practice is lacking.

Bone Marrow Edema May be Found in Normals, Athletes and Military Recruits

Rheumatology has published a study demonstrating that bone marrow edema as measured by magnetic resonance imaging (MRI) may be found in healthy people, but that such changes do not change with intense physical activity.